Procept Biorobotics Corp. (NASDAQ:PRCT) is one of the most promising mid-cap healthcare stocks under $50. On December 12, UBS analyst Danielle Antalffy initiated coverage with a bullish rating on Procept Biorobotics Corp. (NASDAQ:PRCT). She rated the stock as a Buy and estimated a target price of$62. This leads to an upside potential of over 93% from current levels. VILevi/Shutterstock.com Antalffy’s rating is backed by her view of the company’s promising growth prospects, which will be driven by the ...